In Silico Assessment of Drug like Properties of Some Thiadiazole and Oxadiazole Derivatives as HDAC Inhibitors

Authors

  • PARIN Sidat SIDAT Research Scholar, Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Kim, Gujarat, India
  • Janvi V Shah Research Scholar, Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Kim, Gujarat, India
  • Feni B. Shah Research Scholar, Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Kim, Gujarat, India
  • Aishiq H Ganie Research Scholar, Department of Pharmaceutical Chemistry, Shree Dhanvantary Pharmacy College, Kim, Gujarat, India

Keywords:

Thiadiazole, oxadiazole, HDAC inhibitors, Dug likeness properties and biological activity.

Abstract

Purpose: To investigate in silico the drug-like properties of some thiadiazole and oxadiazole derivatives as HDAC inhibitors. Methods: We used Chemdraw Ultra 11.0 to redraw all chemical structures. Furthermore, some applications, such as Bio-Loom for Windows - version 1.5, Molinspiration Property Calculator, and ACD/I-LAB, were used to forecast the drug-like properties of thiadiazole and oxadiazole derivatives, including relative molecular mass (MW), partition coefficient log P (cLog P), number of hydrogen bond donors (HBD), number of hydrogen bond acceptors (HBA), topological polar surface area (TPSA), number of rotatable bonds (NROTB). Furthermore, Lipinski’s rule was utilized to assess druglike qualities. We also investigated the biological activity of drugs. Results: Based on research work, we find out the MWs, HBD, HBA and clogP of the proposed compound are respectively <500, <5, <10, and <5. Additionally, the TPSA score for each compound was 140>2 and NROTB score was >10, so we also got a bioactivity score in the range of >0.00, which indicates a good active molecule. Conclusion: All of the proposed compound has good drug-like characteristics and have shown good oral absorption and bioavailability. The findings also imply that these compounds could be turned in to novel oral HDAC inhibitors for cancer treatment.

References

Chen X, Li H, Tian L, Li Q, Luo J, Zhang Y. Analysis of the Physicochemical Properties of Acaricides Based on Lipinski’s Rule of Five. J Comput Biol. 2020;27(9):1397–406.

Egan WJ, Merz KM, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J Med Chem. 2000;43(21):3867–77.

Maziasz T, Kadambi VJ, Silverman L, Fedyk E, Alden CL. Predictive toxicology approaches for small molecule oncology drugs. Toxicol Pathol. 2010;38(1):148–64.

Clark DE, Pickett SD. Computational methods for the prediction of “drug-likeness.” Drug Discov Today. 2000;5(2):49–58.

Tian S, Wang J, Li Y, Li D, Xu L, Hou T. The application of in silico drug-likeness predictions in pharmaceutical research. Adv Drug Deliv Rev [Internet]. 2015;86:2–10.

Ursu O, Rayan A, Goldblum A, Oprea TI. Understanding drug-likeness. 2011;1(October):760–81.

Lalitha P, Sivakamasundari S. Calculation of molecular lipophilicity and drug likeness for few heterocycles. Orient J Chem. 2010;26(1):135–41.

Verma A. Lead finding from Phyllanthus debelis with hepatoprotective potentials. Asian Pac J Trop Biomed [Internet]. 2012;2(3 SUPPL.):S1735–7. Available from: http://dx.doi.org/10.1016/S2221-1691(12)60486-9

Peng W, Liu YJ, Zhao CB, Huang XS, Wu N, Hu MB, et al. In silico assessment of drug-like properties of alkaloids from Areca catechu L nut. Trop J Pharm Res. 2015;14(4):635–9.

Aoumeur N, Tchouar N, Belaidi S, Ouassaf M, Lanez T, Chtita S. Molecular docking studies for the identifications of novel antimicrobial compounds targeting of staphylococcus aureus. Moroccan J Chem. 2021;9(2):274–89.

Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45(12):2615–23.

Martin YC. A bioavailability score. J Med Chem. 2005;48(9):3164–70.

Downloads

Published

2022-08-29

Issue

Vol. 9 No. 2 (2022)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.